subjects are analyzed again to confirm the accuracy and reliability of the original analytical results. The primary objective of ISR is to assess the performance of the bioanalytical method under real-world conditions, ensuring that results are consistent and reproducible over time.

According to the FDA Guidance for Industry on Bioanalytical Method Validation (2011), a comprehensive understanding of the ISR process is crucial for bioanalytical method validation and is seen as a part of the overall quality system in pharmaceuticals. ISR can be particularly important in the context of therapeutic drug monitoring and pharmacokinetic studies, where small variations in drug concentration can lead to significant therapeutic implications.

Furthermore, ICH Q2(R1) guidelines emphasize that bioanalytical method validation should ensure that the method is suitable for its intended purpose, where ISR plays a vital role in verifying the method’s adequacy in terms of reproducibility. Regulatory agencies across the globe regard ISR as a necessary component of bioanalytical study validation, and understanding its requirements is critical for compliance.

Lifecycle Concepts in ISR Implementation

The lifecycle of incurred sample reanalysis begins with the development of a suitable bioanalytical method through various stages of validation, which then continues throughout the product’s lifecycle. In accordance with the principles outlined in ICH Q8–Q11, ISR-related activities need to be integrated into the entire lifecycle of a biopharmaceutical product, involving stages from development through commercialization.

As part of this lifecycle, ISR implementation involves several key steps:

• Method Development: Initially, the bioanalytical method is developed, where parameters such as specificity, sensitivity, precision, and accuracy are assessed.
• Validation Studies: Following development, validation studies must be conducted to confirm that the method meets predetermined acceptance criteria.
• Incurred Sample Analysis: Samples collected during clinical studies are subjected to ISR to verify the reliability and reproducibility of the quantitative data generated by previously validated methods.
• Data Comparison: Results from the initial analysis are compared against those from the ISR to identify any discrepancies that may require further investigation.

It is critical to plan and execute ISR studies meticulously, as findings will inform regulatory submissions and ultimately impact the approval of pharmaceutical products. Regulatory bodies such as the EMA and MHRA make it explicit that any significant deviations found during ISR can lead to rejection of the study and necessitate additional validation work.

Documentation Requirements for ISR Studies

Technically robust documentation is pivotal in substantiating ISR findings. The documentation should serve as evidence demonstrating compliance with regulatory expectations. Essential documents include but are not limited to:

• Validation Reports: Detailed reports that outline the method validation process, results, and conclusions.
• Standard Operating Procedures (SOPs): SOPs that detail the process for conducting ISR, including sample handling and analysis protocols.
• Sample Analysis Records: Records of the original analyses and ISR studies for reference, showing sample IDs, analyte concentrations, and corresponding data.
• Statistical Analysis Plans: Plans that detail the statistical methods to be used for analyzing ISR results and determining acceptance or rejection of the original data.

Documentation must adhere to the principles of Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP). Comprehensive records support regulatory inspections and office reviews, ensuring that methodologies used in ISR are consistent with those used in initial validations.

Regulatory Expectations for ISR Acceptance Rates

Regulatory expectations for ISR are stringent, focusing on acceptance rates as a measure of reproducibility. According to guidance from the FDA and EMA, an acceptable range for ISR typically lies between 67% and 100%, although this may vary based on the nature of the study and the analyte under investigation.

The regulators emphasize that all samples undergoing ISR must be rerun under the same conditions as the initial analysis. Analyzed samples should cover the entire range of concentrations intended for clinical applications to maintain statistical relevance. The acceptance criteria should be pre-established and outlined clearly prior to conducting the ISR to minimize subjectivity.

Furthermore, the inspection focus during an audit may include a review of ISR outcomes to ensure compliance with expected performance benchmarks. In particular, regulators scrutinize the handling of samples, the execution of the ISR process, and the alignment of reporting with the initial analysis results.

Discrepancies and Investigations in ISR Outcomes

When discrepancies arise between initial analysis and ISR outcomes, deeper investigations are crucial. Regulators mandate that any unexpected deviations be thoroughly documented and analyzed to identify potential sources of error. Such discrepancies could stem from a variety of factors, including:

• Instrumentation Variability: Fluctuations in instrument performance or calibration that impact analytical outcomes.
• Sample Integrity Issues: Compromised sample handling procedures leading to degradation or contamination.
• Operator Error: Human errors during analysis that can affect the reliability of the results.

In cases of significant discrepancies, regulatory authorities expect a comprehensive root-cause analysis to be conducted followed by corrective actions. The findings from this analysis should be well-documented, and any necessary adjustments to the method or process must be validated to ensure future compliance and reliability of data.

Inspection Focus and Compliance in ISR Practices

During regulatory inspections, ISR practices are under the spotlight, with auditors assessing adherence to established protocols and consistency in methodologies. Compliance inspections may occur in various formats, including routine inspections, pre-approval audits, and for-cause inspections triggered by concerns raised during the regulatory review process.

Inspectors typically focus on the following areas during ISR evaluations:

• Method Consistency: Verification that the ISR utilized established methods and maintained analytical consistency at all stages.
• Documentation Review: Examination of all related documentation, including validation reports, SOPs, and ISR records, to ensure thoroughness and accuracy.
• Statistical Analysis Appropriateness: Assessment of the statistical approaches used in analyzing ISR data to validate outcomes appropriately.

Furthermore, compliance with regulations set forth by ICH, EMA, and FDA directly impacts the regulatory submission process. Rejecting non-compliant ISR findings can delay product approval and could result in further scrutiny of the bioanalytical facility involved.

Conclusion

Incurred sample reanalysis (ISR) is an essential part of bioanalytical method validation, reinforcing the principle of reproducibility in analytical testing. Adhering to regulatory expectations as delineated by the US FDA, EMA, and other authorities fortifies the credibility of bioanalytical data relied upon during pharmaceutical development. A thorough understanding of the ISR lifecycle, documentation requirements, acceptance criteria, and inspection foci enables regulatory professionals to uphold compliance and drive successful outcomes in bioanalytical method validation.